The metabolic pathways to create NAD are completely rewired in many tumors.
We have identified "molecular blueprints" for altered NAD metabolism and flux in cancer.
Developing new classes of drugs which target NAD metabolism defects in cancer.
By matching these drugs with unique cancer NAD metabolism profiles will allow for selective tumor targeting over normal tissue.
Rapidly translate new classes of NAD metabolism inhibitors int the clinic and leverage biomarkers to create new therapies with an enhanced therapeutic index.
New Haven, Connecticut, United States